Thomas A Rasmussen

Summary

Publications

  1. doi request reprint Reversal of Latency as Part of a Cure for HIV-1
    Thomas Aagaard Rasmussen
    Department of Infectious Diseases, Aarhus University Hospital, Palle Juul Jensens Boulevard 99, Aarhus, Denmark Electronic address
    Trends Microbiol 24:90-7. 2016
  2. doi request reprint Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
    Thomas A Rasmussen
    Department of Infectious Diseases, Aarhus University Hospital, Denmark Electronic address
    Lancet HIV 1:e13-21. 2014
  3. pmc Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study
    Thomas A Rasmussen
    Department of Infectious Diseases, Aarhus University Hospital, DK 8200 Aarhus N, Denmark
    BMJ 345:e5823. 2012
  4. pmc Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation
    Thomas Aagaard Rasmussen
    Department of Infectious Diseases Aarhus University Hospital Aarhus, Denmark
    Hum Vaccin Immunother 9:993-1001. 2013
  5. pmc Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial
    Thomas A Rasmussen
    Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
    PLoS ONE 7:e32445. 2012
  6. ncbi request reprint Serum procalcitonin in pulmonary tuberculosis
    T A Rasmussen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
    Int J Tuberc Lung Dis 15:251-6, i. 2011
  7. pmc Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy
    Thomas A Rasmussen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
    BMC Infect Dis 11:267. 2011
  8. doi request reprint Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat
    Rikke Olesen
    Infectious Disease Division, Aarhus University Hospital, Aarhus, Denmark
    J Virol 89:10176-89. 2015
  9. doi request reprint Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients
    Ane Bjerg Christensen
    Department of Infectious Diseases, Aarhus University Hospital, 8200 Skejby, Denmark
    Mediators Inflamm 2015:120605. 2015
  10. doi request reprint Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections
    Kasper L Jønsson
    Institute of Biomedicine, Faculty of Health, Aarhus University, Aarhus, Denmark Aarhus Research Centre of Innate Immunology, Aarhus, Denmark
    Antimicrob Agents Chemother 59:3984-94. 2015

Collaborators

Detail Information

Publications13

  1. doi request reprint Reversal of Latency as Part of a Cure for HIV-1
    Thomas Aagaard Rasmussen
    Department of Infectious Diseases, Aarhus University Hospital, Palle Juul Jensens Boulevard 99, Aarhus, Denmark Electronic address
    Trends Microbiol 24:90-7. 2016
    ....
  2. doi request reprint Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
    Thomas A Rasmussen
    Department of Infectious Diseases, Aarhus University Hospital, Denmark Electronic address
    Lancet HIV 1:e13-21. 2014
    ..Activating the expression of latent virus is an approach that might form part of an HIV cure. We assessed the ability of the histone deacetylase inhibitor panobinostat to disrupt HIV-1 latency and the safety of this strategy...
  3. pmc Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study
    Thomas A Rasmussen
    Department of Infectious Diseases, Aarhus University Hospital, DK 8200 Aarhus N, Denmark
    BMJ 345:e5823. 2012
    ..To predict the number of selected outcomes temporally associated but not caused by vaccination, to aid causality assessment of adverse events arising after mass immunisation in a paediatric population...
  4. pmc Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation
    Thomas Aagaard Rasmussen
    Department of Infectious Diseases Aarhus University Hospital Aarhus, Denmark
    Hum Vaccin Immunother 9:993-1001. 2013
    ..We aimed to compare the potential for inducing HIV production and the effect on T-cell activation of potent HDAC inhibitors undergoing clinical investigation...
  5. pmc Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial
    Thomas A Rasmussen
    Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
    PLoS ONE 7:e32445. 2012
    ..Our objective was to compare the bone and renal effects among HIV-infected patients randomized to abacavir or tenofovir-based combination anti-retroviral therapy...
  6. ncbi request reprint Serum procalcitonin in pulmonary tuberculosis
    T A Rasmussen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
    Int J Tuberc Lung Dis 15:251-6, i. 2011
    ..To evaluate the level and prognostic value of procalcitonin (PCT) in a West African out-patient cohort with pulmonary tuberculosis (PTB)...
  7. pmc Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy
    Thomas A Rasmussen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
    BMC Infect Dis 11:267. 2011
    ..Our objective was to evaluate and compare the effect of abacavir on levels of biomarkers associated with cardiovascular risk...
  8. doi request reprint Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat
    Rikke Olesen
    Infectious Disease Division, Aarhus University Hospital, Aarhus, Denmark
    J Virol 89:10176-89. 2015
    ....
  9. doi request reprint Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients
    Ane Bjerg Christensen
    Department of Infectious Diseases, Aarhus University Hospital, 8200 Skejby, Denmark
    Mediators Inflamm 2015:120605. 2015
    ..These results suggest that panobinostat therapy may influence the restoration of mucosal barrier function in these patients. ..
  10. doi request reprint Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections
    Kasper L Jønsson
    Institute of Biomedicine, Faculty of Health, Aarhus University, Aarhus, Denmark Aarhus Research Centre of Innate Immunology, Aarhus, Denmark
    Antimicrob Agents Chemother 59:3984-94. 2015
    ..Altogether, our data indicate that romidepsin-based HIV eradication strategies are unlikely to reseed a latent T cell reservoir, even under suboptimal cART conditions, because romidepsin profoundly restricts de novo HIV infections...
  11. doi request reprint The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
    Ole S Søgaard
    Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
    PLoS Pathog 11:e1005142. 2015
    ..These finding have major implications for future trials aiming to eradicate the HIV-1 reservoir...
  12. doi request reprint Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir
    Jesper F Højen
    Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
    Mol Med 21:337-45. 2015
    ..A relationship with the activation of the monocyte compartment is suggested by the correlation with sCD14 and, interestingly, IL-37 could be related to the size of the total viral HIV-1 reservoir. ..
  13. pmc Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients
    Anni A Winckelmann
    Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
    PLoS ONE 8:e62074. 2013
    ..Reductions in proviral load correlated with increasing levels of HIV specific CD8+ T cells. Further investigation into the potential effect of TLR9 agonists on HIV latency is warranted...